CD4/CD8 T-Cell Selection Affects Chimeric Antigen Receptor (CAR) T-Cell Potency and Toxicity: Updated Results From a Phase I Anti-CD22 CAR T-Cell TrialNirali N. Shah, Terry J. Fry, Steven L. Highfill et al.|Journal of Clinical Oncology|2020Cited by 422
Characterization of HLH-like manifestations as a CRS variant in patients receiving CD22 CAR T cellsDaniel A. Lichtenstein, Nirali N. Shah, Philip Homan et al.|Blood|2021Cited by 194
CD19/22 CAR T cells in children and young adults with B-ALL: phase 1 results and development of a novel bicistronic CARHaneen Shalabi, Nirali N. Shah, Haiying Qin et al.|Blood|2022Cited by 179
Efficacy of second CAR-T (CART2) infusion limited by poor CART expansion and antigen modulationElizabeth M. Holland, Nirali N. Shah, John C. Molina et al.|Journal for ImmunoTherapy of Cancer|2022Cited by 59
Enhanced clinical-scale manufacturing of TCR transduced T-cells using closed culture system modulesJianjian Jin, Steven L. Highfill|Journal of Translational Medicine|2018Cited by 54